State Street Holds 4.4% Of Replimune Common Stock In Passive Position
The September 30 holding comprised 4,174,260 shares, with State Street certifying it was not held to influence control.
State Street reported a 4.4% stake in Replimune, which develops experimental cancer immunotherapies, in a passive ownership disclosure filed with the SEC Tuesday. The 4,174,260-share position reflects holdings as of September 30, rather than a purchase on the filing date.
A Passive Holding, With Shared Votes
State Street certified that the securities were bought and held as part of its ordinary business, without a purpose or effect of changing or influencing Replimune's control.
The position carried shared voting power over 4,080,714 shares and shared authority to dispose of 4,174,260 shares. State Street reported zero sole voting power.
The disclosure also named SSGA Funds Management, State Street Global Advisors Europe and State Street Global Advisors Trust Company.
Cancer Treatments Still In Development
Replimune has no products approved for sale. Its treatments use an engineered herpes simplex virus to destroy tumors and enlist the immune system against cancer, according to its annual report for the fiscal year ended March 31, 2026.
Its lead candidate, RP1, is being tested chiefly in advanced melanoma and other skin cancers. RP2 is being studied in liver cancers and metastatic uveal melanoma, an eye cancer that has spread. Both candidates are injected into tumors.
Replimune's trial partners include Bristol Myers Squibb and Roche. The company also operates a manufacturing facility of approximately 63,000 square feet in Framingham, Massachusetts.
Replimune's market capitalization was $2.1 billion in Tuesday trading as of 10:02 a.m. ET.